June 8, 2012 – For over a year, researchers have cautioned of study results showing that long-term use of the diabetes drug Actos is associated with an increased risk of bladder cancer.
In June of 2011, the FDA first told patients of the dangers after a study by the French Medicines Agency found as much as a 40% increased risk of bladder cancer with Actos use. The findings also prompted Germany and France to ban the drug.
Health Canada also recently issued a warning after their independent study found troubling relations between Actos and bladder cancer. The British Medical Journal published a study on May 31, 2012 by researchers at McGill University in Montreal showing the increased bladder cancer risks from long-term Actos use may actually be as high as 83%.
The study, which tracked over 115,000 patients, found that the risk was specific to those taking Actos, and also increased with use of more than two years. However, until this study, no one has proposed a cause for why the drug may increase risks of bladder cancer.
According to the research team at McGill, a possible explanatory mechanism for the bladder cancer risk is chronic irritation of the bladder from crystal formation caused by the drug. However, they cautioned that further research will be needed to establish this as causative.
So far, thousands of patients have sought legal help after discovering their bladder cancer may be related to Actos. Experts expect as many as 10,000 lawsuits may eventually be filed.
Anyone affected by this drug is urged to speak with an attorney about their legal options, as substantial compensation may be available. However, time is limited.
Since Actos litigation involves a specialized MDL court, it is important to select an attorney with extensive experience in this type of litigation.
The Actos Bladder Cancer Resource Center works only with law firms named to the exclusive steering committee of Actos litigation, or with decades of experience in defective drug litigation.
For more information on the research, side effects and litigation related to the drug Actos, or to speak with a lawyer, contact us today.